DiaSorin’s Luminex Subsidiary to Spin Off Flow Cytometry Business to Cell Analysis Leader

By LabMedica International staff writers
Posted on 15 Feb 2023

Image: With the acquisition, an existing installed base of over 7,000 instruments will be under the Cytek umbrella (Photo courtesy of Luminex)

DiaSorin S.p.A. (‎Saluggia‎, Italy) and Cytek Biosciences, Inc. (Fremont, CA, USA) have announced that Luminex Corporation (Austin, TX, USA), a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.

The FCI business unit, acquired by Luminex in October 2018, is based on both conventional flow cytometry and image-based flow cytometry instrumentation, which provide insights into all facets of cellular phenotypes and morphology. The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel. Following the acquisition, the Cytek umbrella will have an existing installed base of over 7,000 instruments, expanding its global commercial footprint.

With the addition of first-to-market Amnis imaging flow cytometers to its range of cell analysis solutions, Cytek can offer tools to researchers and scientists that combine high-resolution cell images with the speed, sensitivity and phenotyping abilities of flow cytometry. The addition of Guava flow cytometers will expand Cytek’s core instrument offerings, adding cost-effective, entry-level and personal instrument options to broaden the market and research areas serviced by the company.

“We are currently working on several projects that will allow DiaSorin to further growth and strengthen our positioning as a specialty player over the next years,” said Angelo Rago, president of Luminex. “To do so, we need to be extremely focused on the core for our future and, therefore, we decided to sell the Flow Cytometry & Imaging business unit to a dedicated, leading player in the space. We are convinced that Cytek will be able to grow it with success in the future.”

“The talent and technology that come along with this acquisition will bolster our offerings to address the current market and further our mission to provide a complete cell analysis solution to our customers,” added Wenbin Jiang, CEO of Cytek Biosciences. “We look forward to welcoming Luminex’s flow cytometry team into our own and working together to serve our customers and to move cellular research forward.”